SPP1 and major depressive disorder: Conversely, assessment of markers of BMD in humans in treatment for depression following 6 infusions of ketamine demonstrated a sustained decrease in OPN in both male and female patients lasting at least 26 days after the last infusion, with demonstration of sex differences in other bone markers assessed (165).